Lightnews — Scholar-powered news

Seaport Therapeutics @seaporttx.bsky.social · 1d

Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.

Seaport Therapeutics @seaporttx.bsky.social · 2d

Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7

1 1

Seaport Therapeutics @seaporttx.bsky.social · 3d

We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways

1 1

Seaport Therapeutics @seaporttx.bsky.social · 16d

Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/

1

Seaport Therapeutics @seaporttx.bsky.social · 19d

We’re a Fierce Biotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm

1

Seaport Therapeutics @seaporttx.bsky.social · 23d

Looking forward to two upcoming investor conferences: 1x1s & company presentation at Oppenheimer's Private Life Sciences Company Showcase on 9/25 at 11:45am ET & 1x1s at the 5th Annual Needham Private Biotech & MedTech Company Forum, held 10/14-10/15. bit.ly/42z6Fr1

2

Seaport Therapeutics @seaporttx.bsky.social · Sep 11

Pleased to share the first participant has been dosed in our Ph1 study of GlyphAgo™ (SPT-320). This is our 2nd therapeutic candidate in clinical development & represents an important clinical advancement for patients w/GAD. bit.ly/4meQFl0

Seaport Therapeutics @seaporttx.bsky.social · Sep 9

Dan Bonner, Co-Founder & SVP, Platform at Seaport will present at the Neuropsychiatric Drug Development Summit in Boston on 9/11 at 1:30pm to share insights on the discovery & selection of novel lymphatic-targeted prodrug candidates using clinical evidence ter.li/42ap36

Seaport Therapeutics @seaporttx.bsky.social · Sep 9

Congrats to COBENFY & ZURZUVAE teams for 2025 #PrixGalien Best Pharmaceutical Product noms! Kudos to all involved (@PureTechh, Karuna for COBENFY) in the successful journeys, notably Seaport's Dr. Steve Paul for his role in advancing both nominated drugs bit.ly/3V6cx72

Seaport Therapeutics @seaporttx.bsky.social · Aug 28

This summer, the team had a blast together building meaningful connections. From everyday moments to unique outings, these experiences reinforce our bonds & remind us of our shared mission to serve those with #MentalHealth conditions like #depression & #anxiety. Excited for more!

Seaport Therapeutics @seaporttx.bsky.social · Aug 4

We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke

Nature Biotechnology @natbiotech.nature.com · Aug 4

Each year, we highlight companies that received sizeable early-stage funding in the previous year. @seaporttx.bsky.social is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism

Editor’s Pick: Seaport Therapeutics - Nature Biotechnology

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery throug...

go.nature.com

3 1

Seaport Therapeutics @seaporttx.bsky.social · Jul 30

Our CFO, Lauren White, joins Boston Business Journal's “Biotech’s Future – Innovation, AI and our Competitive Edge” panel this Thursday with other industry leaders to discuss the future of biotech & life sciences in MA. Don’t miss this dynamic discussion! bit.ly/44VDFLK

Seaport Therapeutics @seaporttx.bsky.social · Jul 22

CEO @daphnezohar.bsky.social took Brad Loncar @biotechtv.bsky.social on a tour of our office located in heart of Boston’s Seaport District, which is uniquely designed to foster collaboration, happiness & teamwork as we work together to develop new medicines for #depression & #anxiety. Check it out!

BiotechTV @biotechtv.bsky.social · Jul 21

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social

1

Seaport Therapeutics @seaporttx.bsky.social · Jul 18

For @biotechtv.bsky.social's Biotech CEO Sisterhood series, our CEO @daphnezohar.bsky.social spoke to Sophie Kornowski on her journey leading Boston Pharmaceuticals to a $2B deal w/ GSK. Check this out for insights from both leaders on dealmaking, leadership strategies & mentorship: bit.ly/4m55kzG

Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership

Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets, commercialization, partnerships, and, ultimately, executing a successful deal ...

bit.ly

1 1

Seaport Therapeutics @seaporttx.bsky.social · Jul 17

Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB

1 1

Seaport Therapeutics @seaporttx.bsky.social · Jun 30

The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!

1

Seaport Therapeutics @seaporttx.bsky.social · Jun 25

Our Co-founder & Board Chair Dr. Steve Paul was at Royalty Pharma’s #ABI25 for a fireside chat on the neuropsych renaissance. A pioneer in neuropsychiatric drug development, he shared insights into this new era of CNS medicines, including Seaport’s work in #depression & #anxiety

Seaport Therapeutics @seaporttx.bsky.social · May 30

As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org

1 1

Seaport Therapeutics @seaporttx.bsky.social · May 20

This #MentalHealthMonth, we joined @namicommunicate.bsky.social's annual #NAMIWalks to combat stigma & promote mental health awareness. We stand with those affected by mental illness & are dedicated to developing new medicines for #depression & #anxiety. More about NAMI www.nami.org

1 2

Seaport Therapeutics @seaporttx.bsky.social · May 6

Our CMO Tony Loebel & @afspnational.bsky.social board member attended the 2025 Lifesavers Gala to honor progress in the fight against suicide. In recognition of #MentalHealthAwarenessMonth, we're proud Tony represented Seaport to help save lives & bring hope to those affected by suicide.

1

Seaport Therapeutics @seaporttx.bsky.social · May 1

#Depression & #anxiety are among the most common & disabling #mentalhealth conditions. This #MentalHealthAwarenessMonth we're spotlighting our commitment to developing better medicines & reducing the stigma for those dealing w/these conditions. Learn more: www.seaporttx.com

1

Seaport Therapeutics @seaporttx.bsky.social · Apr 29

"Neurology is back” as detailed in Nature Biotech spotlighting "Seaport’s approach, like that of Karuna, is to resurrect drugs that showed clinical efficacy, but which had other issues that limited their impact on patients." Also mentioned $JNJ, $RAPP, $BHVN & others: doi.org/10.1038/s415...

Seaport Therapeutics @seaporttx.bsky.social · Apr 24

We're at #SOBP2025 to present new preclinical data on SPT-320, a novel oral prodrug of agomelatine. SPT-320 increased lymphatic transport >50% compared to <1% agomelatine alone & increased plasma exposure >10-fold. SPT-320 progressing into clinic for #GAD. bit.ly/4ixtOzs

1 3

Seaport Therapeutics @seaporttx.bsky.social · Apr 10

Congrats @daphnezohar.bsky.social, named to @statnews.com #STATUSList, "the ultimate list of leaders in health, medicine, & science," for founding Seaport & raising $325M. “That’s big & her influence on the biotech field extends beyond that” & cofounding Karuna & PureTech bit.ly/4coOF6B

1 9

Seaport Therapeutics @seaporttx.bsky.social · Apr 9

Seaport aims to develop better treatments for depression & anxiety. This commitment comes from our exceptional team, all rowing in the same direction to deliver new drugs to make the lives of patients better. What inspires us daily? Hear from our team!

1 1